Works by Desar, I. M. E.

Results: 8

A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.

Published in:

2010

By:

Desar, I. M. E.;
Timmer-Bonte, J. N. H.;
Burger, D. M.;
van der Graaf, W. T. A.;
van Herpen, C. M. L.

Publication type:

journal article

Double burden: financial toxicity in patients with advanced soft tissue sarcoma at the start of first-line palliative chemotherapy: baseline data from the HOLISTIC study.

Published in:

Supportive Care in Cancer, 2025, v. 33, n. 3, p. 1, doi. 10.1007/s00520-025-09248-5

By:

Roets, E.;
Younger, E.;
Jones, R. L.;
Hollander, D.den;
Desar, I. M. E.;
Young, R. J.;
Oosten, A. W.;
de Haan, J. J.;
Gelderblom, H.;
Steeghs, N.;
van der Graaf, W. T. A.;
Husson, O.

Publication type:

Article

Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients.

Published in:

Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 4, p. 353, doi. 10.1007/s00280-023-04615-7

By:

Westerdijk, K.;
Krens, S. D.;
Steeghs, N.;
van der Graaf, W. T. A.;
Tjwa, E. T. T. L.;
Westdorp, H.;
Desar, I. M. E.;
van Erp, N. P.

Publication type:

Article

Serum bactericidal activity against Helicobacter pylori in patients with hypogammaglobulinaemia.

Published in:

Clinical & Experimental Immunology, 2009, v. 156, n. 3, p. 434, doi. 10.1111/j.1365-2249.2009.03909.x

By:

Desar, I. M. E.;
van Deuren, M.;
Sprong, T.;
Jansen, J. B. M. J.;
Namavar, F.;
Vandenbroucke-Grauls, C. M.;
van der Meer, J. W. M.

Publication type:

Article

Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study.

Published in:

2011

By:

Desar, I. M. E.;
ter Voert, E. G. W.;
Hambrock, Th.;
van Asten, J. J. A.;
van Spronsen, D. J.;
Mulders, P. F. A.;
Heerschap, A.;
van der Graaf, W. T. A.;
van Laarhoven, H. W. M.;
van Herpen, C. M. L.

Publication type:

journal article

Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups.

Published in:

Immunologic Research, 2022, v. 70, n. 2, p. 256, doi. 10.1007/s12026-021-09259-4

By:

Tomassen, T.;
Weidema, M. E.;
Hillebrandt-Roeffen, M. H. S.;
van der Horst, C.;
Desar, I. M. E.;
Flucke, U. E.;
Versleijen-Jonkers, Yvonne M. H.

Publication type:

Article

Predictive factors for toxicity and survival of second-line sunitinib in advanced gastrointestinal stromal tumours (GIST).

Published in:

Acta Oncologica, 2019, v. 58, n. 11, p. 1648, doi. 10.1080/0284186X.2019.1637017

By:

Den Hollander, D.;
Van der Graaf, W. T. A.;
Desar, I. M. E.;
Le Cesne, A.

Publication type:

Article

Capecitabine, irinotecan (CAPIRI) and sunitinib in metastatic colorectal cancer.

Published in:

2013

By:

Boers-Sonderen, M. J.;
Desar, I. M. E.;
Koopman, M.;
Punt, C. J.;
van Herpen, C. M. L.

Publication type:

Letter